NCHR Comments on Screening for Anxiety in Children and Adolescents

May 9, 2022. We agree with USPSTF’s “I” grade recommendation regarding anxiety screening for children 7 years or younger, since there is not sufficient evidence on the benefits and harms of screening for this age group, or to determine the impact of treatments for anxiety in children in this age group. However, regarding screening for anxiety in asymptomatic children between the ages of 8 and 18, we do not agree with USPSTF’s “B” grade recommendation, because of the lack of direct evidence to support USPSTF’s recommendation. 

Read More »

Risks of Benzodiazepines

New research shows benzodiazepines can cause miscarriages in addition to FDA black box warnings about the risks of addiction, dependence, withdrawal, misuse, and abuse. There are safer alternatives to reduce stress and anxiety.

Read More »

New Warnings on Singulair Allergy and Asthma Drug

Due to its psychiatric side effects, the FDA advises that Singulair should not be the first choice treatment for mild allergies, and healthcare providers should weigh the potential risks and benefits before prescribing Singulair for asthma.

Read More »